
Commentary|Podcasts|July 15, 2025
COBRRA Trial Results Raise Questions About VTE Management
The COBBRA trial compared bleeding risk with rivaroxaban vs apixaban in patients with acute venous thromboembolism.
Advertisement
This week, host Craig Beavers sat down with Tara Lech, PharmD, CACP, director of anticoagulation services at Beth Israel Lahey Health, to discuss recent findings from the COBBRA trial, which compared bleeding risk with rivaroxaban vs apixaban in patients with acute venous thromboembolism.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Staging the Heart: NLA and EAS Reveal a New Era of Precision Lipidology and Imaging
2
A Paradigm Shift in Lipid Management: Highlights from the NLA 2026 Scientific Sessions Opening Session
3
Final CLL14 Analysis Confirms Durable Benefit With Fixed-Duration Venetoclax-Obinutuzumab in Frontline CLL
4
FDA Approves Belzutifan Plus Pembrolizumab for Adjuvant Treatment of High-Risk Clear Cell RCC
5


































































































































